Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 132.76 Million EUR | 15.06% |
| 2022 | 115.39 Million EUR | 10.51% |
| 2021 | 104.41 Million EUR | 9.03% |
| 2020 | 95.76 Million EUR | 18.36% |
| 2019 | 80.9 Million EUR | 101.92% |
| 2018 | 40.07 Million EUR | -25.93% |
| 2017 | 54.09 Million EUR | -12.1% |
| 2016 | 61.54 Million EUR | -19.62% |
| 2015 | 76.56 Million EUR | 15.95% |
| 2014 | 66.03 Million EUR | 1.75% |
| 2013 | 64.9 Million EUR | 1179.36% |
| 2012 | 5.07 Million EUR | -3.7% |
| 2011 | 5.26 Million EUR | -4.93% |
| 2010 | 5.54 Million EUR | 3.36% |
| 2009 | 5.36 Million EUR | 38.74% |
| 2008 | 3.86 Million EUR | 23.69% |
| 2007 | 3.12 Million EUR | 8.17% |
| 2006 | 2.88 Million EUR | 6.61% |
| 2005 | 2.7 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 159.03 Million EUR | 19.78% |
| 2024 Q2 | 160.54 Million EUR | 0.95% |
| 2023 Q1 | 112.78 Million EUR | -2.26% |
| 2023 Q3 | 134.89 Million EUR | 32.13% |
| 2023 FY | 132.76 Million EUR | 15.06% |
| 2023 Q4 | 132.76 Million EUR | -1.58% |
| 2023 Q2 | 102.09 Million EUR | -9.47% |
| 2022 Q3 | 146 Million EUR | 22.71% |
| 2022 Q4 | 115.39 Million EUR | -20.97% |
| 2022 FY | 115.39 Million EUR | 10.51% |
| 2022 Q1 | 48 Million EUR | -54.02% |
| 2022 Q2 | 118.98 Million EUR | 147.87% |
| 2021 Q2 | 101.31 Million EUR | 3.96% |
| 2021 Q4 | 104.41 Million EUR | 0.0% |
| 2021 Q1 | 97.46 Million EUR | 1.77% |
| 2021 FY | 104.41 Million EUR | 9.03% |
| 2020 Q4 | 95.76 Million EUR | -5.39% |
| 2020 Q1 | 90.84 Million EUR | 12.28% |
| 2020 Q2 | 102.72 Million EUR | 13.08% |
| 2020 Q3 | 101.21 Million EUR | -1.47% |
| 2020 FY | 95.76 Million EUR | 18.36% |
| 2019 Q4 | 80.9 Million EUR | 1.05% |
| 2019 FY | 80.9 Million EUR | 101.92% |
| 2019 Q3 | 80.06 Million EUR | 14.35% |
| 2019 Q2 | 70.02 Million EUR | -3.13% |
| 2019 Q1 | 72.28 Million EUR | 80.39% |
| 2018 FY | 40.07 Million EUR | -25.93% |
| 2018 Q1 | 41.15 Million EUR | -23.92% |
| 2018 Q3 | 40.31 Million EUR | 3.29% |
| 2018 Q4 | 40.07 Million EUR | -0.61% |
| 2018 Q2 | 39.03 Million EUR | -5.16% |
| 2017 Q2 | 54.14 Million EUR | -5.88% |
| 2017 Q1 | 57.52 Million EUR | -6.53% |
| 2017 Q4 | 54.09 Million EUR | 4.08% |
| 2017 FY | 54.09 Million EUR | -12.1% |
| 2017 Q3 | 51.97 Million EUR | -4.01% |
| 2016 Q1 | 69.98 Million EUR | -8.59% |
| 2016 Q2 | 64.81 Million EUR | -7.39% |
| 2016 Q3 | 62.86 Million EUR | -3.01% |
| 2016 Q4 | 61.54 Million EUR | -2.1% |
| 2016 FY | 61.54 Million EUR | -19.62% |
| 2015 Q4 | 76.56 Million EUR | -5.26% |
| 2015 FY | 76.56 Million EUR | 15.95% |
| 2015 Q2 | 83.38 Million EUR | -3.1% |
| 2015 Q1 | 86.05 Million EUR | 30.31% |
| 2015 Q3 | 80.81 Million EUR | -3.08% |
| 2014 Q2 | 63.63 Million EUR | -0.68% |
| 2014 FY | 66.03 Million EUR | 1.75% |
| 2014 Q4 | 66.03 Million EUR | 2.13% |
| 2014 Q3 | 64.65 Million EUR | 1.61% |
| 2014 Q1 | 64.06 Million EUR | -1.29% |
| 2013 FY | 64.9 Million EUR | 1179.36% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 46.75 Million EUR | 0.0% |
| 2013 Q3 | 44.73 Million EUR | -4.32% |
| 2013 Q4 | 64.9 Million EUR | 45.08% |
| 2012 Q4 | 5.07 Million EUR | 0.0% |
| 2012 Q2 | 4.6 Million EUR | 0.0% |
| 2012 FY | 5.07 Million EUR | -3.7% |
| 2011 FY | 5.26 Million EUR | -4.93% |
| 2011 Q4 | 5.26 Million EUR | 0.0% |
| 2011 Q2 | 6.16 Million EUR | 0.0% |
| 2010 FY | 5.54 Million EUR | 3.36% |
| 2010 Q4 | 5.54 Million EUR | 0.0% |
| 2010 Q2 | 5.75 Million EUR | 0.0% |
| 2009 FY | 5.36 Million EUR | 38.74% |
| 2009 Q4 | 5.36 Million EUR | 0.0% |
| 2008 FY | 3.86 Million EUR | 23.69% |
| 2007 FY | 3.12 Million EUR | 8.17% |
| 2006 FY | 2.88 Million EUR | 6.61% |
| 2005 FY | 2.7 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -11958.856% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -197.04% |
| Adocia SA | 4.54 Million EUR | -2824.405% |
| Aelis Farma SA | 2.04 Million EUR | -6382.813% |
| Biophytis S.A. | 3.11 Million EUR | -4167.695% |
| Advicenne S.A. | 15.89 Million EUR | -735.229% |
| genOway Société anonyme | 5.51 Million EUR | -2305.522% |
| IntegraGen SA | 642.28 Thousand EUR | -20571.358% |
| Medesis Pharma S.A. | 1.2 Million EUR | -10964.0% |
| Neovacs S.A. | 650 Thousand EUR | -20325.846% |
| NFL Biosciences SA | 39.2 Thousand EUR | -338567.959% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -2947.578% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -6672.741% |
| Sensorion SA | 1.24 Million EUR | -10599.236% |
| Theranexus Société Anonyme | 2.46 Million EUR | -5295.498% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -3306.054% |
| TheraVet SA | 1 Million EUR | -13168.852% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -1822.502% |
| argenx SE | 15.35 Million EUR | -764.713% |
| BioSenic S.A. | 15.57 Million EUR | -752.552% |
| Celyad Oncology SA | 902 Thousand EUR | -14619.29% |
| DBV Technologies S.A. | 4.52 Million USD | -2833.451% |
| Galapagos NV | 4.94 Million EUR | -2585.437% |
| Genfit S.A. | 62.25 Million EUR | -113.272% |
| GeNeuro SA | 6.49 Million EUR | -1945.007% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -38495.349% |
| Innate Pharma S.A. | 30.6 Million EUR | -333.783% |
| Inventiva S.A. | 25.61 Million EUR | -418.301% |
| MaaT Pharma SA | 5.42 Million EUR | -2347.336% |
| MedinCell S.A. | 52.8 Million EUR | -151.455% |
| Nanobiotix S.A. | 41.66 Million EUR | -218.694% |
| Onward Medical N.V. | 16.3 Million EUR | -714.228% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -3747.662% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -273.91% |
| Oxurion NV | 117 Thousand EUR | -113376.923% |
| Pharming Group N.V. | 123.65 Million EUR | -7.368% |
| Poxel S.A. | 40.14 Million EUR | -230.738% |
| GenSight Biologics S.A. | 1.04 Million EUR | -12568.702% |
| Transgene SA | 17 Thousand EUR | -780888.235% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 95.387% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |